Literature DB >> 22483283

Changes in cannabinoid receptor subtype 1 activity and interaction with metabotropic glutamate subtype 5 receptors in the periaqueductal gray-rostral ventromedial medulla pathway in a rodent neuropathic pain model.

Enza Palazzo1, Livio Luongo, Giulia Bellini, Francesca Guida, Ida Marabese, Serena Boccella, Francesca Rossi, Sabatino Maione, Vito de Novellis.   

Abstract

This study analyzed the effect of intra-ventrolateral periaqueductal grey (VL PAG) cannabinoid receptor (CB) stimulation on pain responses and rostral ventromedial medulla (RVM) neural activity in the chronic constriction injury (CCI) model of neuropathic pain in rats. Interaction between CB1 and metabotropic glutamate 1 and 5 (mGlu(1)/mGlu(5)) receptors was also investigated together with the expression of the CB1 receptor associated Gαi3 and cannabinoid receptor interacting 1a (CRIP 1a) proteins and the endocannabinoid synthesising and hydrolysing enzymes. In rats not subjected to CCI-induced pain, intra-VL PAG (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate (WIN 55,212-2) (2-4-8 nmol), a CB receptor agonist, increased the tail flick latency and changed the ongoing activity of RVM OFF and the tail flick-related activity of the ON and OFF cells, accordingly. These effects were prevented by SR141716A and MPEP, selective CB(1) and mGlu(5) receptor antagonists, respectively, though not by CPCCOEt, a selective mGlu(1) receptor antagonist. A higher dose up to 16 nmol of WIN 55,212-2 was necessary to increase tail flick latency and change ON and OFF cell activity in CCI rats. Consistently, CCI rats showed a decrease in the expression of CB(1) receptors, NAPE-PLD, Gαi3 and CRIP 1a proteins;the expression of diacylglycerol lipase A (DAGLA) was increased while fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL) did not change. As in control rats, MPEP and SR141716A also blocked WIN 55,212-2- induced effects in CCI rats. These data demonstrate a down regulation of the endocannabinoid system and a functional interaction between mGlu(5) and CB(1) receptors for cannabinoid-mediated effect in the PAG-RVM pain circuitry in neuropathic pain inflicted rats.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22483283     DOI: 10.2174/187152712800269731

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  10 in total

Review 1.  Cannabinoids in the descending pain modulatory circuit: Role in inflammation.

Authors:  Courtney A Bouchet; Susan L Ingram
Journal:  Pharmacol Ther       Date:  2020-01-29       Impact factor: 12.310

Review 2.  Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain.

Authors:  Henry L Blanton; Jennifer Brelsfoard; Nathan DeTurk; Kevin Pruitt; Madhusudhanan Narasimhan; Daniel J Morgan; Josée Guindon
Journal:  Drugs       Date:  2019-06       Impact factor: 9.546

3.  Compensatory Activation of Cannabinoid CB2 Receptor Inhibition of GABA Release in the Rostral Ventromedial Medulla in Inflammatory Pain.

Authors:  Ming-Hua Li; Katherine L Suchland; Susan L Ingram
Journal:  J Neurosci       Date:  2017-01-18       Impact factor: 6.167

4.  Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation.

Authors:  Yatendra Mulpuri; Vincent N Marty; Joseph J Munier; Ken Mackie; Brian L Schmidt; Herbert H Seltzman; Igor Spigelman
Journal:  Neuropharmacology       Date:  2018-07-05       Impact factor: 5.250

5.  Paracetamol is a centrally acting analgesic using mechanisms located in the periaqueductal grey.

Authors:  David André Barrière; Fawzi Boumezbeur; Romain Dalmann; Roberto Cadeddu; Damien Richard; Jérémy Pinguet; Laurence Daulhac; Philippe Sarret; Kevin Whittingstall; Matthieu Keller; Sébastien Mériaux; Alain Eschalier; Christophe Mallet
Journal:  Br J Pharmacol       Date:  2020-01-22       Impact factor: 8.739

Review 6.  Peripheral gating of pain signals by endogenous lipid mediators.

Authors:  Daniele Piomelli; Oscar Sasso
Journal:  Nat Neurosci       Date:  2014-01-28       Impact factor: 24.884

7.  Loss of dopamine D1 receptors and diminished D1/5 receptor-mediated ERK phosphorylation in the periaqueductal gray after spinal cord lesion.

Authors:  Pamela J Voulalas; Yadong Ji; Li Jiang; Jamila Asgar; Jin Y Ro; Radi Masri
Journal:  Neuroscience       Date:  2016-12-05       Impact factor: 3.590

8.  Role of Cannabinoid Receptors in Crocin-Induced Hypoalgesia in Neuropathic Pain in Rats.

Authors:  Abbas Ali Vafaei; Hossein Ali Safakhah; Simin Jafari; Azin Tavasoli; Ali Rashidy-Pour; Ali Ghanbari; Seyed Ali Seyedinia; Parnia Tarahomi
Journal:  J Exp Pharmacol       Date:  2020-04-28

Review 9.  Dynamic changes to the endocannabinoid system in models of chronic pain.

Authors:  Devi Rani Sagar; James J Burston; Stephen G Woodhams; Victoria Chapman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

10.  Novel analgesic effects of melanin-concentrating hormone on persistent neuropathic and inflammatory pain in mice.

Authors:  Jae-Hwan Jang; Ji-Yeun Park; Ju-Young Oh; Sun-Jeong Bae; Hyunchul Jang; Songhee Jeon; Jongpil Kim; Hi-Joon Park
Journal:  Sci Rep       Date:  2018-01-15       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.